Semaglutide Shows Promise for Liver Health, Obesity Impacts Vaccine Response
Recent health news highlights several significant developments. Semaglutide, a GLP-1 receptor agonist, has been shown to improve liver health independently of weight loss by targeting liver sinusoidal endothelial cells. This discovery could lead to new treatments for liver conditions. Additionally, a study published in The Journal of Immunology suggests that obesity may impair vaccine response due to defects in germinal centers, affecting antibody production. This finding could influence vaccine design for individuals with obesity. Furthermore, a phase II trial has shown promising results for pancreatic cancer treatment, with elraglusib combined with chemotherapy doubling survival rates after one year. 
